tazobactam has been researched along with ofloxacin in 6 studies
| Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (ofloxacin) | Trials (ofloxacin) | Recent Studies (post-2010) (ofloxacin) |
|---|---|---|---|---|---|
| 1,327 | 153 | 694 | 6,484 | 976 | 1,346 |
| Protein | Taxonomy | tazobactam (IC50) | ofloxacin (IC50) |
|---|---|---|---|
| DNA gyrase subunit A | Escherichia coli K-12 | 1.5 | |
| DNA gyrase subunit B | Escherichia coli K-12 | 1.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Kirikae, T; Kitao, T; Miyoshi-Akiyama, T | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Burgess, DS; Nathisuwan, S | 1 |
| Bethe, U; Breuer, K; Cornely, OA; Diehl, V; Fätkenheuer, G; Karthaus, M; Reichert, D; Salzberger, B; Schwonzen, M; Seifert, H; Ullmann, AJ; Wicke, T | 1 |
| Balasubramanium, G; Elangovan, R; Gupta, SS; Lodha, T; Muthulakshmi, T; Perumal, V; Sivaraman, GK; Visnuvinayagam, S; Yadav, A | 1 |
1 trial(s) available for tazobactam and ofloxacin
| Article | Year |
|---|---|
Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bacterial Infections; Disease Susceptibility; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; Fever of Unknown Origin; Humans; Immunocompromised Host; Levofloxacin; Male; Middle Aged; Neoplasms; Neutropenia; Ofloxacin; Penicillanic Acid; Piperacillin; Prospective Studies; Safety; Tazobactam; Treatment Outcome | 2004 |
5 other study(ies) available for tazobactam and ofloxacin
| Article | Year |
|---|---|
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
Topics: Acetylation; Acetyltransferases; Aminoglycosides; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Integrons; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa.
Topics: Cefepime; Cephalosporins; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sensitivity and Specificity; Tazobactam | 2002 |
Prevalence of S. aureus and/or MRSA from seafood products from Indian seafood products.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cefoxitin; Gentamicins; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Multilocus Sequence Typing; Ofloxacin; Piperacillin; Prevalence; Rifampin; Seafood; Serine; Staphylococcal Infections; Staphylococcus aureus; Sulbactam; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination; Virulence Factors | 2022 |